VHL mutation
|
Neuroendocrine Tumor
|
VHL mutation
|
Neuroendocrine Tumor
|
belzutifan Sensitive: A1 - Approval
|
belzutifan Sensitive: A1 - Approval
|
VHL mutation
|
CNS Tumor
|
VHL mutation
|
CNS Tumor
|
belzutifan Sensitive: A1 - Approval
|
belzutifan Sensitive: A1 - Approval
|
VHL mutation
|
RCC
|
VHL mutation
|
RCC
|
belzutifan Sensitive: A1 - Approval
|
belzutifan Sensitive: A1 - Approval
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
belzutifan Sensitive: C1 - Off-label
|
belzutifan Sensitive: C1 - Off-label
|
VHL mutation
|
GBM
|
VHL mutation
|
GBM
|
belzutifan Sensitive: C1 - Off-label
|
belzutifan Sensitive: C1 - Off-label
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
PT2385 Sensitive: C2 – Inclusion Criteria
|
PT2385 Sensitive: C2 – Inclusion Criteria
|
VHL mutation
|
Neuroendocrine Tumor
|
VHL mutation
|
Neuroendocrine Tumor
|
PT2385 Sensitive: C3 – Early Trials
|
PT2385 Sensitive: C3 – Early Trials
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
VHL mutation
|
RCC
|
VHL mutation
|
RCC
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
VHL mutation
|
Cholangiocarcinoma
|
VHL mutation
|
Cholangiocarcinoma
|
sunitinib Sensitive: C4 – Case Studies
|
sunitinib Sensitive: C4 – Case Studies
|
VHL mutation
|
RCC
|
VHL mutation
|
RCC
|
doxorubicin hydrochloride Sensitive: D – Preclinical
|
doxorubicin hydrochloride Sensitive: D – Preclinical
|